Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards.


Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
22 May 2024
Historique:
medline: 22 5 2024
pubmed: 22 5 2024
entrez: 22 5 2024
Statut: aheadofprint

Résumé

To update the ASCO-Oncology Nursing Society (ONS) standards for antineoplastic therapy administration safety in adult and pediatric oncology and highlight current standards for antineoplastic therapy for adult and pediatric populations with various routes of administration and location. ASCO and ONS convened a multidisciplinary Expert Panel with representation of multiple organizations to conduct literature reviews and add to the standards as needed. The evidence base was combined with the opinion of the ASCO-ONS Expert Panel to develop antineoplastic safety standards and guidance. Public comments were solicited and considered in preparation of the final manuscript. The standards presented here include clarification and expansion of existing standards to include home administration and other changes in processes of ordering, preparing, and administering antineoplastic therapy; the advent of immune effector cellular therapy; the importance of social determinants of health; fertility preservation; and pregnancy avoidance. In addition, the standards have added a fourth verification. Standards are provided for which health care organizations and those involved in all aspects of patient care can safely deliver antineoplastic therapy, increase the quality of care, and reduce medical errors.Additional information is available at www.asco.org/standards and www.ons.org/onf.

Identifiants

pubmed: 38776491
doi: 10.1200/OP.24.00216
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

OP2400216

Auteurs

Robert D Siegel (RD)

Bon Secours St Francis Cancer Center, Greenville, SC.

Kristine B LeFebvre (KB)

Oncology Nursing Society (ONS), Pittsburg, PA.

Sarah Temin (S)

American Society of Clinical Oncology (ASCO), Alexandria, VA.

Amy Evers (A)

University of Pennsylvania Health System, Philadelphia, PA.

Lisa Barbarotta (L)

Smilow Cancer Hospital and Yale Cancer Center, New Haven, CT.

Ronda M Bowman (RM)

American Society of Clinical Oncology (ASCO), Alexandria, VA.

Alexandre Chan (A)

University of California, Irvine, Chao Family Comprehensive Cancer Center, National Cancer Centre Singapore, Irvine, CA.

David W Dougherty (DW)

University of Pennsylvania Health System, Philadelphia, PA.

Michael Ganio (M)

ASHP (American Society of Health-System Pharmacists), Bethesda, MD.

Bradley Hunter (B)

Intermountain Health, Salt Lake City, UT.

Meredith Klein (M)

American Society of Clinical Oncology (ASCO), Alexandria, VA.

Tamara P Miller (TP)

Emory University/Children's Healthcare of Atlanta, Atlanta, GA.

Therese Marie Mulvey (TM)

Massachusetts General Cancer Center, Boston, MA.

Amanda Ouzts (A)

Huntsville Hospital, Huntsville, AL.

Martha Polovich (M)

University of Maryland School of Medicine, Baltimore, MD.

Maritza Salazar-Abshire (M)

Department of Nursing Education, The University of Texas MD Anderson Cancer Center, Houston, TX.

Elaine Z Stenstrup (EZ)

City of Hope National Medical Center, Duarte, CA.

Susan Tsai (S)

Ohio State University Comprehensive Cancer Center, Columbus, OH.

MiKaela M Oslen (MM)

Johns Hopkins Hospital and Health System, Baltimore, MD.

Classifications MeSH